Dr. Simo Schwartz Jr, principal investigator of the Pharmacological Targeting and Release group at Vall d'Hebron Research Institute (VHIR) and strategic director of the Biobank and Biomodel at Vall d'Hebron Barcelona Campus Hospital, has been selected as a member of one of the European Medicines Agency (EMA) Operational Expert Groups. Specifically, the group of experts that assists the Working Group on New Therapies and Technologies in Nanomedicines of the EMA (NTWP Operational Expert Group on nanomedicines).

The objective of this advisory committee is to support the development of guidelines to technically and legally regulate the creation of new therapies and technologies in the area of nanomedicine. The group is currently working on the development of a guideline on the treatment and development of nanomedicines with non-biodegradable parts. Dr. Schwartz Jr. is a leading international scientist in this field with extensive professional experience in the sector. He currently serves as president of the European Association of Nanomedicine.